It’s a type of drug called a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1 ... following chart highlights the basics of Mounjaro’s dosage.
announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback